Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Current Assets (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Current Assets for 13 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 14.75% year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Dec 2025, up 14.75%, and an annual FY2025 reading of $2.5 million, up 14.75% over the prior year.
  • Current Assets was $2.5 million for Q4 2025 at Abvc Biopharma, down from $3.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $9.8 million in Q2 2022 and bottomed at $1.5 million in Q1 2025.
  • Average Current Assets over 5 years is $3.8 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw Current Assets skyrocketed 503.76% in 2021, then plummeted 78.25% in 2023.
  • Year by year, Current Assets stood at $7.7 million in 2021, then tumbled by 60.97% to $3.0 million in 2022, then crashed by 44.54% to $1.7 million in 2023, then skyrocketed by 31.58% to $2.2 million in 2024, then rose by 14.75% to $2.5 million in 2025.
  • Business Quant data shows Current Assets for ABVC at $2.5 million in Q4 2025, $3.3 million in Q3 2025, and $2.8 million in Q2 2025.